Findings

What do systematic reviews say?

6 questions · 6 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 16.7%Low 4 · 66.7%Moderate 1 · 16.7%High 0 · 0%

RISPERIDONE vs PERHENAZINE ‒ long‐term data

Leaving the study early · people with both severe mental illness and substance misuse

RISPERIDONE showed no clear difference in leaving the study early: any reason compared with PERHENAZINE ‒ long‐term data (low certainty).

1 finding from 1 review

Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse 2018 · Cochrane Headline outcomes only
RR 1.05 [0.92, 1.2]
1 study · 281 participants
Low

RISPERIDONE vs ZIPRASIDONE ‒ long‐term data (> 12 months)

Leaving the study early · people with both severe mental illness and substance misuse

RISPERIDONE showed no clear difference in leaving the study early: any reason compared with ZIPRASIDONE ‒ long‐term data (> 12 months) (low certainty).

1 finding from 1 review

Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse 2018 · Cochrane Headline outcomes only
RR 0.96 [0.85, 1.1]
1 study · 240 participants
Low

RISPERIDONE vs CLOZAPINE ‐ all data short term

Leaving the study early · people with both severe mental illness and substance misuse

It is very uncertain whether RISPERIDONE changes leaving the study early ‒ any reason compared with CLOZAPINE ‐ all data short term (very low certainty).

1 finding from 1 review

Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse 2018 · Cochrane Headline outcomes only
RR 0.49 [0.1, 2.51]
2 studies · 45 participants
Very low

RISPERIDONE DEPOT vs GENERAL ORAL ANTIPSYCHOTICS

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT showed no clear difference in leaving the study early: Any reason ‐ long term compared with GENERAL ORAL ANTIPSYCHOTICS (moderate certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 1.24 [0.98, 1.57]
2 studies · 467 participants
Moderate

RISPERIDONE DEPOT vs TYPICAL DEPOT ANTIPSYCHOTICS

Leaving the study early · patients with schizophrenia

RISPERIDONE DEPOT may leads to higher leaving the study early for any reason ‐ long term compared with TYPICAL DEPOT ANTIPSYCHOTICS (low certainty).

1 finding from 1 review

Risperidone (depot) for schizophrenia 2016 · Cochrane Headline outcomes only
RR 3.05 [1.12, 8.31]
1 study · 62 participants
Low

RISPERIDONE vs QUETIAPINE

Leaving the study early · people with both severe mental illness and substance misuse

RISPERIDONE showed no clear difference in leaving the study early: 1. any reason, long term (>12 months) compared with QUETIAPINE ‒ short‐ and long‐term data (low certainty).

1 finding from 1 review

Risperidone versus other antipsychotics for people with severe mental illness and co‐occurring substance misuse 2018 · Cochrane Headline outcomes only
RR 0.96 [0.86, 1.07]
1 study · 294 participants
Low